A Pan‐Cancer Study of Tumour‐Associated Efferocytosis Core Genes and Preliminary Exploration of TIMD4 in Renal Cell Carcinoma
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Hongze Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Phagocytosis, Membrane Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province.
Abstract (Originalsprache)
Efferocytosis plays a crucial role in maintaining the stability of the immune microenvironment. Increasing research indicates that efferocytosis core genes (ECGs) are not only widely expressed in immune cells, but also expressed at significant levels in tumour cells, impacting tumour progression. However, the comprehensive effects of ECGs on cancer prognosis and the immune microenvironment remain underexplored. This study analysed data from 33 tumour types to assess the expression, diagnostic and prognostic values of ECGs as well as gene modification landscapes. It also predicted the correlation between ECGs, the immune microenvironment and responses to immunotherapy, revealing that lower ECGs expression levels were associated with better immunotherapy responses in various cancers. Additionally, molecular docking studies simulated the interactions between TIMD4 and its sensitive drugs, facilitating targeted drug development. Finally, both in vitro and in vivo experiments confirmed that silencing TIMD4 could effectively inhibit the proliferation and invasion of renal cell carcinoma. Overall, TIMD4 can be used as an important biomarker for tumour prognosis and immunotherapy response, providing new insights into the mechanisms of tumour immune microenvironment and progression, as well as a novel therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of China Medical University, Shenyang, China.
- Department of Orthopedics, The First Affiliated Hospital of China Medical University, Shenyang, China.
- Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, the First Affiliated Hospital of China Medical University, Shen…
- Department of Pathology and Pathophysiology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
- Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang, China.
- Department of Vascular Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Förderung
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Li, H., Zhang, J., Zhang, Y., Li, Z., Han, Y., & Lun, Y. (2025). A Pan‐Cancer Study of Tumour‐Associated Efferocytosis Core Genes and Preliminary Exploration of TIMD4 in Renal Cell Carcinoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70671
Vancouver
Li H, Zhang J, Zhang Y, Li Z, Han Y, Lun Y. A Pan‐Cancer Study of Tumour‐Associated Efferocytosis Core Genes and Preliminary Exploration of TIMD4 in Renal Cell Carcinoma. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70671
BibTeX
@article{Li2025,
author = {Li, Hongze and Zhang, Jiaqi and Zhang, Yixiao and Li, Zixuan and Han, Yuxi and Lun, Yu},
title = {A Pan‐Cancer Study of Tumour‐Associated Efferocytosis Core Genes and Preliminary Exploration of TIMD4 in Renal Cell Carcinoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70671}
}
EUVIMED